Matrix Oncology LP v. Priority Healthcare

CourtCourt of Appeals for the Fifth Circuit
DecidedJune 30, 2009
Docket08-10191
StatusUnpublished

This text of Matrix Oncology LP v. Priority Healthcare (Matrix Oncology LP v. Priority Healthcare) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fifth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Matrix Oncology LP v. Priority Healthcare, (5th Cir. 2009).

Opinion

IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT United States Court of Appeals Fifth Circuit

FILED June 30, 2009

No. 08-10191 Charles R. Fulbruge III Clerk

Matrix Oncology, L.P.

Plaintiff-Appellee v.

Priority Healthcare Corp.

Defendant-Appellant

Appeal from the United States District Court for the Northern District of Texas

Before GARWOOD, GARZA, and OWEN, Circuit Judges. PER CURIAM:* This appeal results from a jury verdict rendered in favor of plaintiff- appellee, Matrix Oncology, L.P. (Matrix). The jury awarded Matrix $3,000,000 in damages for negligent misrepresentations committed by defendant-appellant, Priority Healthcare Corporation (Priority). The verdict was returned on November 9, 2007, and the district court entered a Final Judgment for Matrix on November 13, 2007. On November 27, 2007, Priority filed a Renewed Motion

* Pursuant to 5TH CIR . R. 47.5, the court has determined that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5TH CIR . R. 47.5.4.

1 for Judgment as a Matter of Law, which the district court denied on February 4, 2008. Priority now appeals to this Court. For the following reasons, we AFFIRM. I. FACTS AND PROCEEDINGS BELOW On January 30, 2004, Matrix and Priority entered into a joint-venture agreement to form Matrix Oncology, L.L.C. (the LLC), an enterprise to purchase and sell cancer-fighting drugs. Specifically, the LLC would operate as a group purchasing organization to get drug-pricing discounts for members of its oncology clinic. Matrix owned forty percent of the LLC and Priority owned sixty percent. The LLC was successful from the start, generating almost $1.5 million in profits in its first eleven months of operation. In October 2004, Matrix and Priority began discussions to dissolve or “unwind” the LLC by having Priority purchase Matrix’s forty percent interest in the LLC. During these discussions, John Rivers, the senior vice president in charge of cancer drugs for Priority, informed Matrix of merger negotiations between Priority and One Equity Partners (OEP) whereby OEP would acquire Priority’s distribution business, which included Priority’s interest in the LLC. It was believed that such a combination would add considerable value to Priority and its subsidiaries, including the LLC. Prompted by these negotiations between Priority and OEP, both Matrix and Priority wanted Matrix to receive an additional payment if, after Matrix’s sale of its forty percent LLC interest to Priority, OEP acquired Priority’s cancer- drug distribution section and the LLC. Matrix representative William Jordan 1 told Rivers (of Priority) that Matrix wanted this additional payment as

1 Specifically, Jordan is one of six members of Matrix Genpar, L.L.C. and a limited partner in Matrix Holdings, L.P. Matrix Genpar L.L.C. is the general partner of Matrix Holdings, L.P. and Matrix Holdings, L.P is the sole partner of Matrix.

2 compensation for Matrix’s loss of any future sale of the LLC that would have resulted in material gain to Matrix had it not first sold its interest in the LLC to Priority. Rivers recommended that Jordan and Tom Barr, another Matrix representative,2 meet with Rebecca Shanahan, Priority’s executive vice president of strategic ventures and general counsel, regarding dissolution of the LLC. On January 12, 2005, Steve Cosler, Priority’s CEO, received a phone call from Dom Meffe, senior vice president of specialty pharmacy for Express Scripts (ESI) and president and chief executive officer of CuraScript (a subsidiary of ESI). In that call, Meffe (of ESI) informed Cosler (of Priority) that ESI was interested in acquiring Priority’s business.3 The very same day, Cosler reported that phone call to Priority’s Chairman of the Board of Directors and single largest shareholder, William Bindley, who then informed three other Priority Board members. Cosler also informed Stephen Saft, Priority’s Chief Financial Officer, of ESI’s interest on January 12. On January 20, 2005, Jordan (of Matrix), Barr (of Matrix), Shanahan (of Priority), and Guy Bryant, an executive vice president of Priority, met to discuss the unwinding of the LLC. During this meeting, Jordan asked Shanahan if Priority was discussing a merger or acquisition with any other companies. Shanahan told Jordan that she knew of no other offers at that time, and Matrix does not dispute that Shanahan did not know of other offers at the January 20 meeting. On February 9, 2005, Shanahan (Priority’s general counsel) sent an

2 Barr is also a member of Matrix Genpar, L.L.C. and a limited partner of Matrix Holdings, L.P. 3 This was not the first contact between these companies regarding a possible merger or acquisition. ESI and Priority had discussed ESI’s possibility of acquiring Priority in the fall of 2003. During the 2003 discussions, the two companies began a due-diligence review and ESI proposed a buyout, but the negotiations fell through a few months later when ESI acquired another company.

3 email to Priority representatives Rivers, Bryant, and Saft explaining that she had advised Wayne Whitman, Matrix’s counsel, that there were no current plans or activities to sell Priority. Draft agreements dissolving the LLC were exchanged between the parties on January 28, 2005 and February 21, 2005. In the drafts, an acquisition of the LLC by OEP was the only listed transaction that would trigger any additional payment to Matrix. In mid-February, Meffe (of ESI) again contacted Cosler (of Priority) and stated that ESI’s Board of Directors continued to be interested in doing a business deal with Priority. On February 23, Cosler presented this information to the Priority Board of Directors, stating that ESI had a “strong interest” in acquiring Priority. Shanahan was present at this meeting and admits that she learned of ESI’s interest a few days prior to the board meeting. On March 4, 2005, Priority and Matrix signed a Membership Transfer Agreement (the MTA). Jordan testified that a few days prior to this signing, he again asked Shanahan if Priority was involved in merger or acquisition discussions with any company other than OEP, and Shanahan answered no. Priority disputes that this inquiry took place only a few days before March 4, as evidenced by Shanahan’s February 9 email. According to the terms of the MTA, Priority paid $600,000 for Matrix’s interest in the LLC. The parties also agreed that if there were a third-party sale of the LLC to OEP after Matrix received its $600,000, Matrix would receive an additional payment of $3 million: “Priority is currently in negotiations with a third party, [OEP] . . . . In the event that Priority or the [LLC] shall, as a result of any Transaction between the [LLC] or Priority and OEP or its affiliates . . . enter into any joint venture with OEP or its affiliates or sell any ownership interest in the [LLC], . . . the [LLC] and Priority shall .

4 . . pay [Matrix] the aggregate sum of $3,000,000 . . . . As used herein, ‘Transaction’ shall mean any agreement between and among Priority or the [LLC] (or any of their respective affiliates) and OEP or its affiliates that is a joint venture, sale or exchange of ownership interest in the [LLC] to OEP or its affiliates within the eighteen (18) months after [March 4, 2005].” Membership Transfer Agreement, § 3. The MTA also contains broad releases. The MTA contains a release by Matrix of “all Transferor Released Claims,” defining “Claims” as “any and all manner of claims . . . whether now known or hereafter discovered.” Id. § 1. “Transferor Released Claims” includes any “statement, omission, duty, action or failure to act” arising from the joint venture and related agreements or “any other relationship or transaction” between the parties “from the beginning of the world through the Effective Date.” Id. §1.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. Davis
226 F.3d 346 (Fifth Circuit, 2000)
Foradori v. Harris
523 F.3d 477 (Fifth Circuit, 2008)
Gustafson v. Alloyd Co.
513 U.S. 561 (Supreme Court, 1995)
Forest Oil Corp. v. McAllen
268 S.W.3d 51 (Texas Supreme Court, 2008)
Bridgen v. Scott
456 F. Supp. 1048 (S.D. Texas, 1978)
Coker v. Coker
650 S.W.2d 391 (Texas Supreme Court, 1983)
McCamish, Martin, Brown & Loeffler v. F.E. Appling Interests
991 S.W.2d 787 (Texas Supreme Court, 1999)
Schlumberger Technology Corp. v. Swanson
959 S.W.2d 171 (Texas Supreme Court, 1997)
Federal Land Bank Ass'n of Tyler v. Sloane
825 S.W.2d 439 (Texas Supreme Court, 1992)
Von Graffenreid v. Craig
246 F. Supp. 2d 553 (N.D. Texas, 2003)
MCN Energy Enterprises, Inc. v. Omagro De Colombia, L.D.C.
98 S.W.3d 766 (Court of Appeals of Texas, 2003)
Haralson v. E.F. Hutton Group, Inc.
919 F.2d 1014 (Fifth Circuit, 1990)

Cite This Page — Counsel Stack

Bluebook (online)
Matrix Oncology LP v. Priority Healthcare, Counsel Stack Legal Research, https://law.counselstack.com/opinion/matrix-oncology-lp-v-priority-healthcare-ca5-2009.